Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Tiotropium · 1 trial · 1 indication
noncompartmental analysis
| Arm | Type | Description |
|---|---|---|
| Test Product | EXPERIMENTAL | tiotropium pMDI 2 inhalations |
| Commercial Product | ACTIVE_COMPARATOR | tiotropium pMDI 2 inhalations |
| Name | Type | Description |
|---|---|---|
| Tiotropium | DRUG | inhalation |
Inclusion Criteria: * Healthy Volunteer * Willing and able to give informed consent * Willing to withhold all alcoholic beverages for 48 hours and all xanthine- containing foods and beverages for 24 hours prior to reporting to clinic * Subjects must agree to use an adequate method of contraception ...
Tiotropium is an investigational small molecule being studied in healthy volunteers. It is currently in Phase 1 clinical development, with a completed trial evaluating its pharmacokinetics. The drug is not approved and remains under investigation.
Tiotropium is being developed by 3M Company, traded on the New York Stock Exchange under the ticker MMM. The company is conducting early-stage clinical research on this small molecule drug candidate.
Tiotropium is in Phase 1 clinical development. One Phase 1 trial has been completed, involving 40 healthy participants. The drug is investigational and has not received regulatory approval.
Tiotropium has one completed clinical trial, NCT03246581, a two-period 21-day crossover study comparing the pharmacokinetics of tiotropium from two inhalers. The trial enrolled 40 healthy volunteers in the United Kingdom and was actively controlled.
Tiotropium is the active ingredient in Spiriva, a medication used for respiratory conditions. In this development program, tiotropium is being studied as an inhaled formulation in healthy volunteers to assess its pharmacokinetic profile.